CD46 and neoplasm: Recently, it was reported that MV has significant anti-tumor activity against GBM and glioma stem cells in vitro and in vivo, a sensitivity that is at least in part explained by the overexpression of the MV receptor CD46 in brain tumor cell lines [16].